Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
2 ADRA2A [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
3 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
4 ADRA2B [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
5 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00514 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
6 ADRA2C [2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D01205 Dexmedetomidine [13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
7 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
8 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D00632 Dobutamine [3] 57, 58, 215
9 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03879 Dobutamine [3] 57, 58, 215
10 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03880 Dobutamine [3] 57, 58, 215
11 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D03881 Dobutamine [3] 57, 58, 215
12 ADRB1 [11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
13 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
14 ADRB2 [9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
15 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D00483 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
16 ADRB3 [8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08443 Propranolol [7] 6, 158, 167, 215, 227, 278, 296
17 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D00357 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
18 AGTR1 [16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy D08146 Losartan [18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
19 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
20 GRIN1 [18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
21 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
22 GRIN2A [19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
23 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
24 GRIN2B [19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
25 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
26 GRIN2C [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
27 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
28 GRIN2D [15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine [8] 2, 4, 6, 13, 70, 113, 156, 215
29 NR3C2 [1] Aldosterone-regulated sodium reabsorption D01115 Eplerenone [1] 215
30 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D00320 Fentanyl [4] 46, 70, 215, 231
31 OPRM1 [3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D01399 Fentanyl [4] 46, 70, 215, 231
32 PLG [4] Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Staphylococcus aureus infection, Influenza A D01136 Tranexamic acid [6] 46, 70, 215, 227, 288, 299
33 CACNA1I [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D01303 Flunarizine [4] 58, 86, 149, 215
34 CACNA1I [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D07971 Flunarizine [4] 58, 86, 149, 215
35 CACNA1H [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D01303 Flunarizine [4] 58, 86, 149, 215
36 CACNA1H [7] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D07971 Flunarizine [4] 58, 86, 149, 215
37 CACNA1G [8] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D01303 Flunarizine [4] 58, 86, 149, 215
38 CACNA1G [8] MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D07971 Flunarizine [4] 58, 86, 149, 215